reference/8686204

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8686204

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	2087
issn	1029-2403 1042-8194
issueIdentifier	9
pageRange	2083-2087
publicationName	Leukemia & Lymphoma
startingPage	2083
bibliographicCitation	Malcikova J, Razga F, Jurcek T, Dvorakova D, Zackova D, Toskova M, Sebejova L, Smardova J, Oltova A, Vankova G, Jurackova L, Trbusek M, Pospisilova S, Mayer J, Racil Z. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. Leuk Lymphoma. 2013 Sep;54(9):2083–7. doi: 10.3109/10428194.2012.762649. PMID: 23289360.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_49308797678f7b7d3579e5a7d5863385 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7136-2680 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd29416148f4af38311ba107899e7c21 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_881417f3fe5d49913d97b50252f7b506 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5eecbb4f0fdf022d999e7fcf7bfd610b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9c17201f1f3dd41b7b2f253763745457 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f0f678c7b4f077cc07e5df9c0dcf6835 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f919fe02d3852da92bf2af023e9ae86f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4ebfd88531586dfbdb219904e7c17949 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d5947cbe0504d03635310802b55e2268 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8e6a9048a3fc738e02e08f43fa6824c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c9edad96113adda3bfa343cf818184d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_335843d91a91b3771538ad8258cd0d3e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dd45ddc440b556663a5cfc5a8c7a68ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c38647918660f79e9960dab7ed94a6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ddb930975658ec27ac02d00f57ca5d8
date	201302
identifier	https://pubmed.ncbi.nlm.nih.gov/23289360 https://doi.org/10.3109/10428194.2012.762649
isPartOf	https://portal.issn.org/resource/ISSN/1029-2403 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2306 https://portal.issn.org/resource/ISSN/1042-8194
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	TheBCR–ABL1T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy
discusses	http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0024527 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0004703 http://id.nlm.nih.gov/mesh/M0585531
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009154 http://id.nlm.nih.gov/mesh/D002869 http://id.nlm.nih.gov/mesh/D015464Q000235 http://id.nlm.nih.gov/mesh/D016044Q000235 http://id.nlm.nih.gov/mesh/D019008Q000235
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D015464Q000188 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D015464Q000473 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D015464Q000401 http://id.nlm.nih.gov/mesh/D003062 http://id.nlm.nih.gov/mesh/D047428Q000627
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9727 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_472a53b1a4ec3818b8392773f5523355

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID613

Total number of triples: 58.